Landscapes / Targets
CSF1
13 drugs act on CSF1, in 36 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs13
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Approved | 30 Dec 2026Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis and 3 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Incyte +1 |
Approved | 6 Jan 2027Phase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 6 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Chronic Graft-versus-host-disease | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved in China | 31 May 2028Phase 2/3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 May 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Metastatic Pancreatic Cancer | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | Aug 2028Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Aug 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis and 5 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Pulmonary Arterial Hypertension | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 30 Jan 2027Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma and 3 more | ||||
| Open drug page | |||||
— |
Phase 3 | 28 Feb 2027Phase 2 trial completes | |||
| Next date | 28 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 29 Nov 2027Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 29 Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST) and 4 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | — | |||
| How it works | An antibody | ||||
| Also tested for | TGCT | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 1/2 | 30 Dec 2027Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Esophageal Cancer, Gastric Cancer and 3 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Solid Tumor | ||||
| Open drug page | |||||
— |
Phase 1 | Aug 2027Phase 1 trial completes | |||
| Next date | Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Food Effect in Healthy Volunteers | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Turning Point Therapeutics +1 · Public BMY |
Phase 1 | — | ||
| How it works | Blocks a kinase | ||||
| Also tested for | Advanced Solid Tumor, Metastatic Solid Tumors and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 13 of 13 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026